HAP Trading’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

HAP Trading’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-68,011	Closed	-$4.71M	–	898
2024 Q1	$4.71M	Buy	+68,011	New	+$4.67M	0.54%	41
2021 Q4	–	Sell	-14,460	Closed	-$607K	–	2932
2021 Q3	$539K	Buy	+14,460	New	+$503K	0.02%	658
2020 Q3	–	Sell	-19,227	Closed	-$439K	–	1959
2020 Q2	$494K	Buy	+19,227	New	+$389K	0.03%	437
2017 Q4	–	Sell	-14,966	Closed	-$236K	–	1194
2017 Q3	$236K	Buy	+14,966	New	+$220K	0.01%	485

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HAP Trading's ITCI Position: Q2 2024 in Review

HAP Trading sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 68,011 shares — an estimated $4.71M sold.

HAP Trading first reported a position in ITCI in Q3 2017 and held it in 4 quarters. The position peaked at $4.71M in Q1 2024. 375 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

HAP Trading reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
HAP Trading sold 68,011 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $4.71M.
HAP Trading first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 4 quarters.
HAP Trading's Intra-Cellular Therapies Inc. position peaked at $4.71M in Q1 2024.
375 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.